|
Active substance |
Abiraterone acetate |
|
Holder |
Janssen-Cilag |
|
Status |
Closed |
|
Indication |
Treatment of newly diagnosed with high risk Metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) and prednisone or prednisolone. |
|
Public documents |
|
|
Last update |
05/10/2018 |
Zytiga®
Last updated on 02/10/2024